Stock Analysis, Dividends, Split History
AMD / Advanced Micro Devices, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.
|Market Cap ($M)||19,275.75|
|Enterprise Value ($M)||19,497.75|
|Book Value ($M)||879.00|
|Book Value / Share||0.90|
|Price / Book||21.93|
|NCAV / Share||n/a|
|Price / NCAV||n/a|
|Income Statement (mra) ($M)|
|Sales Revenue Goods Net||5,329,000,000.00|
|Sales Revenue Net||5,329,000,000.00|
|Earnings Per Share Basic||0.04|
|Earnings Per Share Diluted||0.04|
|Cash Flow Statement (mra) ($M)|
|Cash From Operations||68.00|
|Cash from Investing||-114.00|
|Cash from Financing||-114.00|
|Identifiers and Descriptors|
|Central Index Key (CIK)||2488|
|007903957 007903909 007903907 007903958|
|SIC 3674 - Semiconductors and Related Devices|
Stock splits are used by Advanced Micro Devices, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.
2017-09-28 - Asif
We are a global semiconductor company with facilities around the world. Within the global semiconductor industry, we offer primarily: x86 microprocessors, as standalone devices or as incorporated as an accelerated processing unit (APU), chipsets, discrete graphics processing units (GPUs) and professional graphics processors; and server and embedded processors, semi-custom System-on-Chip (SoC) products and technology for game consoles. We also license portions of our intellectual property portfolio. In this section, we will describe the general financial condition and the results of operations of Advanced Micro Devices, Inc. and its wholly-owned subsidiaries (collectively, “us,” “our” or “AMD”), including a discussion of our results of operations for the quarter and six months ended July 1, 2017 compared to the quarter and six months ended June 25, 2016 , an analysis of changes in our financial condition and a discussion of our contractual obligations. We believe our fin...
2018-08-20 - Asif
Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...
2018-08-20 - Asif
Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...
2018-08-20 - Asif
General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="https://www.sec.gov/A...
Related News Stories
Broader U.S. equities continued to rally Monday, with some outsized moves in a few specific names. It’s summer trading, and absent a rise in volatility, we could see equities slowly grind higher. Remember, don’t fight price! Here’s a look at our top stock trades for the week. (58-4)
Equities entered the weekend a stone’s throw from new highs. And with Friday’s rally placing the S&P 500 oh so close to overhead resistance, many stocks are flashing potential breakout patterns. The appeal of breakout stocks is the clean entry and the good chance for follow through. (27-0)
The past few weeks have been tough ones for Intel (NASDAQ:INTC) shareholders, as Intel stock has peeled back from its early June peak of $57.60 to a multi-month low near $47… an 18% setback. But, it can’t be said the punishment wasn’t deserved. (29-2)
When it comes to chipmaker Advanced Micro Devices (NASDAQ:AMD), I have played the part of both the bull and the bear. When AMD stock dropped below $10 in early April 2018, I played the part of the bull, seeing the sell-off as a big buying opportunity for long-term investors into a company with broad exposure to multiple secular growth markets. (23-2)
The week started off with the financial crisis in Turkey rattling investors. Bank shares were smacked as investors worried about the problem spreading to other countries. The Turkish lira traded down as much as 20% vs. the dollar after President Trump authorized the doubling of metal tariffs on the country. Monday was the fourth straight day of losses for the S&P 500. (118-0)
Silicon Investor Message Boards
This table lists all message boards related to AMD / Advanced Micro Devices, Inc. on message board site Silicon Investor.
as of ET